Commonwealth of Virginia
Office of the Attorney General
202 North Ninth Street
For media inquiries only, contact:
Charlotte Gomer, Press Secretary
Mobile: (804) 512-2552
ATTORNEY GENERAL HERRING FILES WIDE-RANGING LAWSUIT AGAINST 26 DRUG MAKERS AND 10 EXECUTIVES FOR CONSPIRACY TO FIX PRICES ON MORE THAN 80 GENERIC DRUGS
~ This is the third lawsuit filed by Attorney General Herring in ongoing, expanding antitrust investigation of the generic drug industry ~
RICHMOND (June 10, 2020) – Attorney General Mark R. Herring today joined a coalition of 51 states in filing the third lawsuit stemming from an ongoing antitrust investigation into a widespread conspiracy by generic drug manufacturers to artificially inflate and manipulate prices, reduce competition, and unreasonably restrain trade for generic drugs sold across the United States. This new Complaint, filed in the U.S. District Court for the District of Connecticut, focuses on 80 topical generic drugs that account for billions of dollars of sales in the United States. The Complaint names 26 corporate Defendants and 10 individual Defendants. The lawsuit seeks disgorgement, civil penalties, and actions by the court to restore competition to the generic drug market.
The topical drugs at the center of the Complaint include creams, gels, lotions, ointments, shampoos, and solutions used to treat a variety of skin conditions, pain, and allergies.
"These drug companies chose profit over keeping people safe and healthy,” said Attorney General Mark Herring. "Too many Virginians know the struggle of paying incredibly high drug prices, and in many cases the generic alternative may not have offered a lower-cost alternative because of this alleged price fixing. Virginians should never have to choose between paying for critical medication or paying for food, rent or utilities because of artificially inflated prices. My colleagues and I will continue to combat illegal price fixing in the generic drug market and hold drug companies and decision makers accountable.”
The Complaint stems from an ongoing investigation built on evidence from several cooperating witnesses at the core of the conspiracy, a massive document database of over 20 million documents, and a phone records database containing millions of call detail records and contact information for over 600 sales and pricing individuals in the generics industry. Among the records obtained by the states is a two-volume notebook containing the contemporaneous notes of one of the States' cooperators that memorialized his discussions during phone calls with competitors and internal company meetings over a period of several years.
Between 2007 and 2014, three generic drug manufacturers, Taro, Perrigo, and Fougera (now Sandoz) sold nearly two-thirds of all generic topical products dispensed in the United States. The multistate investigation has uncovered comprehensive, direct evidence of unlawful agreements to minimize competition and raise prices on dozens of topical products. The Complaint alleges longstanding agreements among manufacturers to ensure a "fair share” of the market for each competitor, and to prevent "price erosion” due to competition.
The Complaint is the third to be filed in an ongoing wide-ranging multistate antitrust investigation of the generic drug industry. The first Complaint, still pending in the U.S. District Court in the Eastern District of Pennsylvania, was filed in 2016 and now includes 18 corporate Defendants, two individual Defendants, and 15 generic drugs. Two former executives from Heritage Pharmaceuticals, Jeffery Glazer and Jason Malek, have entered into settlement agreements and are cooperating with the attorneys general working group in that case. The second Complaint, also pending in the U.S. District Court in the Eastern District of Pennsylvania, was filed in 2019 against Teva Pharmaceuticals and 19 of the nation's largest generic drug manufacturers. That Complaint names 16 individual senior executive Defendants. The States are currently preparing for trial on that Complaint.
Corporate Defendants in the current Complaint:
- Sandoz, Inc.
- Actavis Holdco U.S., Inc.
- Actavis Elizabeth LLC
- Actavis Pharma, Inc.
- Amneal Pharmaceuticals, Inc.
- Amneal Pharmaceuticals, LLC
- Aurobindo Pharma USA, Inc.
- Bausch Health Americas, Inc.
- Bausch Health, US LLC
- Fougera Pharmaceuticals, Inc.
- G&W Laboratories, Inc.
- Glenmark Pharmaceuticals Inc., USA
- Greenstone LLC
- Lannett Company, Inc.
- Lupin Pharmaceuticals, Inc.
- Mallinckrodt Inc.
- Mallinckrodt plc
- Mallinckrodt LLC
- Mylan Inc.
- Mylan Pharmaceuticals Inc.
- Perrigo New York, Inc.
- Pfizer, Inc.
- Sun Pharmaceutical Industries, Inc.
- Taro Pharmaceuticals USA, Inc.
- Teligent, Inc.
- Wockhardt USA, LLC
- Ara Aprahamian, Vice President of Sales and Marketing at Defendant Taro Pharmaceuticals USA, Inc.
- Mitchell Blashinsky, Vice President of Marketing for Generics at Defendant Taro Pharmaceuticals USA, Inc. from January 2007 – May 2012, and Vice President of Sales and Marketing at Defendant Glenmark Pharmaceuticals, Inc., USA from June 2012 – March 2014
- Douglas Boothe, Chief Executive Officer of Defendant Actavis from August 2008 – December 2012 and Executive Vice President and General Manager of Defendant Perrigo New York, Inc. from January 2013 – July 2016
- James Grauso, former Vice President of Sales and Marketing at Defendant G&W Laboratories from January 2010 – December 2011; Senior Vice President of Commercial Operations for Defendant Aurobindo from December 2011 – January 2014; and Executive Vice President, N.A. Commercial Operations at Defendant Glenmark from February 2014 – present
- Walt Kaczmarek, Senior Director of National Accounts, Vice President of National Accounts, and Senior Vice President of commercial Operations for Fougera Pharmaceuticals, a division of Nycomed US, Inc. (currently part of Defendant Sandoz, Inc.) from November 2004 – November 2012 and Vice President – General Manager and President of Multi-Source Pharmaceuticals for Defendant Mallinckrodt from November 2013 – August 2016.
- Armando Kellum, former Vice President of Contracting and Business Analytics at Defendant Sandoz
- Kurt Orlofski, President and Chief Executive Officer for Defendant Wockhardt USA from April 2007 – August 2009 and President of Defendant G&W Labs, Inc. from September 2009 – December 2016.
- Mike Perfetto, Vice President of Sales and Marketing for Defendant Actavis from August 2003 – January 2013 and Chief Commercial Officer for Defendant Taro from January 2013 through his recent retirement from the company.
- Erika Vogel-Baylor, former Vice President of Sales and Marketing for Defendant G&W Labs, Inc. since July 2011
- John Wesolowski, Senior Vice President of Commercial Operations for Defendant Perrigo since February 2004
Drugs listed in the complaint as subject to price-fixing and market allocation agreements:
- Acetazolamide Tablets
- Adapalene Cream
- Alclometasone Dipropionate Cream
- Alclometasone Dipropionate Ointment
- Ammonium Lactate Cream
- Ammonium Lactate Lotion
- Betamethasone Dipropionate Cream
- Betamethasone Dipropionate Lotion
- Betamethasone Valerate Cream
- Betamethasone Valerate Lotion
- Betamethasone Valerate Ointment
- Bromocriptine Mesylate Tablets
- Calcipotriene Solution
- Calcipotriene Betamethasone Dipropionate Ointment
- Carbamazepine ER Tablets
- Cefpodoxime Proxetil Oral Suspension
- Cefpodoxime Proxetil Tablets
- Ciclopirox Cream
- Ciclopirox Shampoo
- Ciclopirox Solution
- Clindamycin Phosphate Cream
- Clindamycin Phosphate Gel
- Clindamycin Phosphate Lotion
- Clindamycin Phosphate Solution
- Clobetasol Propionate Cream
- Clobetasol Propionate Emollient Cream
- Clobetasol Propionate Gel
- Clobetasol Propionate Ointment
- Clobetasol Propionate Solution
- Clotrimazole 1% Cream
- Clotrimazole Betamethasone Dipropionate Cream
- Clotrimazole Betamethasone Dipropionate Lotion
- Desonide Cream
- Desonide Lotion
- Desonide Ointment
- Desoximetasone Ointment
- Econazole Nitrate Cream
- Eplerenone Tablets
- Erythromycin Base/Ethyl Alcohol Solution
- Ethambutol HCL Tablets
- Fluocinolone Acetonide Cream
- Fluocinolone Acetonide Ointment
- Fluocinonide .1% Cream
- Fluocinonide Gel
- Fluocinonide Ointment
- Fluocinonide Solution
- Fluticasone Propionate Lotion
- Griseofulvin Microsize Tablets
- Halobetasol Propionate Cream
- Halobetasol Propionate Ointment
- Hydrocortisone Acetate Suppositories
- Hydrocortisone Valerate Cream
- Imiquimod Cream
- Ketoconazole Cream
- Latanoprost Drops
- Lidocaine Ointment
- Methazolamide Tablets
- Methylphenidate HCL Tablets
- Methylphenidate HCL ER Tablets
- Metronidazole Cream
- Metronidazole .75% Gel
- Metronidazole .1% Gel
- Metronidazole Lotion
- Mometasone Furoate Cream
- Mometasone Furoate Ointment
- Mometasone Furoate Solution
- Nafcillin Sodium Injectable Vials
- Nystatin Ointment
- Nystatin Triamcinolone Cream
- Nystatin Triamcinolone Ointment
- Oxacillin Sodium Injectable Vials
- Phenytoin Sodium ER Capsules
- Pioglitazone HCL Metformin HCL Tablets
- Prochlorperazine Maleate Suppositories
- Promethazine HCL Suppositories
- Tacrolimus Ointment
- Terconazole Cream
- Triamcinolone Acetonide Cream
- Triamcinolone Acetonide Ointment
- Triamcinolone Acetonide Paste
Attorney General Herring joined the attorneys general of Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Territory of Guam, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, Tennessee, Utah, U.S. Virgin Islands, Vermont, Washington, West Virginia and Wisconsin in filing the complaint.
# # #